Home World News No EFS Benefit From Adding Atezolizumab To 1-Year BCG Therapy In BCG-Naive... World News No EFS Benefit From Adding Atezolizumab To 1-Year BCG Therapy In BCG-Naive Patients With High-Risk Non-Muscle-Invasive Bladder Cancer By Ogkologos - November 17, 2025 372 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ALBAN (GETUG-AFU 37) study Source RELATED ARTICLESMORE FROM AUTHOR Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR Exposure to Antibiotics, Specifically Fluoroquinolones, Before Treatment with Immune Checkpoint Inhibitor... March 6, 2023 EMA Recommends Extension of Indications for Pirtobrutinib April 24, 2025 The Risk of irAEs After Immune Checkpoint Inhibitor Therapy May Not... March 1, 2021 What Caregivers Should Know About End-of-Life Care Issues for People With... September 8, 2022 Load more HOT NEWS Rate of Suicides Related to Cancer Is Declining Combining existing drugs improves prostate cancer survival Dr. Alan S. Rabson, Long-Time NCI Deputy Director and Cancer Research... Beloved Kindergarten Teacher Who Inspired Her Community Dies of Breast Cancer...
